Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis
Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.
Related Articles
Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC
Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.
Zongertinib Could Alter SOC in HER2-Mutated Advanced NSCLC
John V. Heymach, MD, PhD, discusses updated findings from the phase 1b Beamion LUNG-1 trial of zongertinib in HER2-mutated advanced NSCLC.
The OncFive: Top Oncology Articles for the Week of 5/11
The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.
Adjuvant Aumolertinib Boosts DFS in Stage II-IIIB, EGFR-Mutated NSCLC
Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.
FDA Grants Fast Track Designation to BI-1808 in Select Cutaneous T-Cell Lymphoma
BI-1808 has received FDA fast track designation for the treatment of patients with select cutaneous T-cell lymphoma subtypes.
RSVP
Register Here *Thursday, May 29, 2025 | 7 – 10 PM (central) Adler Planetarium 1300 South DuSable Lake Shore Drive Chicago, IL 60605 Dress: Business…
Clinical Insights Into Treatment Approach for Metastatic HER+ mBC Patient Case
Panelists discuss how they approach treatment sequencing for HER2-positive (HER2+) metastatic breast cancer (mBC) after progression on first-line therapy, including considerations for trastuzumab deruxtecan and…
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Inavolisib Plus Palbociclib/Fulvestrant Earns Positive CHMP Opinion for PIK3CA-Mutated, ER+/HER2– Advanced Breast Cancer
The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.
Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL
Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.